AAPL   381.91 (-0.46%)
MSFT   207.07 (-3.09%)
FB   239.00 (-2.48%)
GOOGL   1,512.23 (-1.74%)
AMZN   3,104.00 (-3.00%)
BABA   251.67 (-3.58%)
MU   49.46 (-2.45%)
GE   6.70 (+0.15%)
TSLA   1,497.06 (-3.08%)
AMD   53.59 (-4.10%)
T   29.76 (-1.23%)
F   6.06 (-0.66%)
GILD   76.68 (+0.47%)
DIS   116.22 (-2.61%)
NFLX   525.50 (-4.23%)
BAC   24.19 (+0.71%)
BA   175.65 (-1.56%)
AAPL   381.91 (-0.46%)
MSFT   207.07 (-3.09%)
FB   239.00 (-2.48%)
GOOGL   1,512.23 (-1.74%)
AMZN   3,104.00 (-3.00%)
BABA   251.67 (-3.58%)
MU   49.46 (-2.45%)
GE   6.70 (+0.15%)
TSLA   1,497.06 (-3.08%)
AMD   53.59 (-4.10%)
T   29.76 (-1.23%)
F   6.06 (-0.66%)
GILD   76.68 (+0.47%)
DIS   116.22 (-2.61%)
NFLX   525.50 (-4.23%)
BAC   24.19 (+0.71%)
BA   175.65 (-1.56%)
AAPL   381.91 (-0.46%)
MSFT   207.07 (-3.09%)
FB   239.00 (-2.48%)
GOOGL   1,512.23 (-1.74%)
AMZN   3,104.00 (-3.00%)
BABA   251.67 (-3.58%)
MU   49.46 (-2.45%)
GE   6.70 (+0.15%)
TSLA   1,497.06 (-3.08%)
AMD   53.59 (-4.10%)
T   29.76 (-1.23%)
F   6.06 (-0.66%)
GILD   76.68 (+0.47%)
DIS   116.22 (-2.61%)
NFLX   525.50 (-4.23%)
BAC   24.19 (+0.71%)
BA   175.65 (-1.56%)
AAPL   381.91 (-0.46%)
MSFT   207.07 (-3.09%)
FB   239.00 (-2.48%)
GOOGL   1,512.23 (-1.74%)
AMZN   3,104.00 (-3.00%)
BABA   251.67 (-3.58%)
MU   49.46 (-2.45%)
GE   6.70 (+0.15%)
TSLA   1,497.06 (-3.08%)
AMD   53.59 (-4.10%)
T   29.76 (-1.23%)
F   6.06 (-0.66%)
GILD   76.68 (+0.47%)
DIS   116.22 (-2.61%)
NFLX   525.50 (-4.23%)
BAC   24.19 (+0.71%)
BA   175.65 (-1.56%)
Log in

NYSE:TAROTaro Pharmaceutical Industries Stock Price, Forecast & News

$65.63
+0.50 (+0.77 %)
(As of 07/13/2020 04:00 PM ET)
Add
Compare
Today's Range
$65.53
Now: $65.63
$66.72
50-Day Range
$64.21
MA: $67.29
$69.08
52-Week Range
$56.07
Now: $65.63
$99.69
Volume793 shs
Average Volume26,962 shs
Market Capitalization$2.51 billion
P/E Ratio10.32
Dividend YieldN/A
Beta0.79
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. The company sells and distributes its products principally to drug industry wholesalers, drug store chains, mass merchandisers, healthcare institutions, and private pharmacies. The company was founded in 1959 and is based in Haifa Bay, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Alkaloida Chemical Company Zrt.
Read More
Taro Pharmaceutical Industries logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.39 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone914-345-9000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$644.77 million
Cash Flow$7.00 per share
Book Value$55.15 per share

Profitability

Net Income$244.24 million

Miscellaneous

Employees1,464
Market Cap$2.51 billion
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive TARO News and Ratings via Email

Sign-up to receive the latest news and ratings for TARO and its competitors with MarketBeat's FREE daily newsletter.

Taro Pharmaceutical Industries (NYSE:TARO) Frequently Asked Questions

How has Taro Pharmaceutical Industries' stock been impacted by COVID-19 (Coronavirus)?

Taro Pharmaceutical Industries' stock was trading at $64.44 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, TARO stock has increased by 1.8% and is now trading at $65.63. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Taro Pharmaceutical Industries?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Taro Pharmaceutical Industries in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Taro Pharmaceutical Industries.

When is Taro Pharmaceutical Industries' next earnings date?

Taro Pharmaceutical Industries is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Taro Pharmaceutical Industries.

How were Taro Pharmaceutical Industries' earnings last quarter?

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) issued its earnings results on Tuesday, May, 19th. The company reported $1.42 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $1.53 by $0.11. The company earned $174.94 million during the quarter, compared to the consensus estimate of $168.25 million. Taro Pharmaceutical Industries had a return on equity of 11.94% and a net margin of 37.88%. View Taro Pharmaceutical Industries' earnings history.

What price target have analysts set for TARO?

1 brokerages have issued 12-month target prices for Taro Pharmaceutical Industries' shares. Their forecasts range from $96.00 to $96.00. On average, they anticipate Taro Pharmaceutical Industries' share price to reach $96.00 in the next twelve months. This suggests a possible upside of 46.3% from the stock's current price. View analysts' price targets for Taro Pharmaceutical Industries.

Has Taro Pharmaceutical Industries been receiving favorable news coverage?

News headlines about TARO stock have been trending very negative recently, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Taro Pharmaceutical Industries earned a news sentiment score of -3.2 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about Taro Pharmaceutical Industries.

Are investors shorting Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries saw a decline in short interest in the month of June. As of June 30th, there was short interest totaling 133,500 shares, a decline of 7.4% from the June 15th total of 144,200 shares. Based on an average trading volume of 35,300 shares, the days-to-cover ratio is presently 3.8 days. Currently, 1.5% of the shares of the stock are short sold. View Taro Pharmaceutical Industries' Current Options Chain.

Who are some of Taro Pharmaceutical Industries' key competitors?

What other stocks do shareholders of Taro Pharmaceutical Industries own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Taro Pharmaceutical Industries investors own include Gilead Sciences (GILD), Broadcom (AVGO), Bausch Health Companies (BHC), Pfizer (PFE), Teva Pharmaceutical Industries (TEVA), Skyworks Solutions (SWKS), GW Pharmaceuticals PLC- (GWPH), Jazz Pharmaceuticals (JAZZ), Mallinckrodt (MNK) and Novo Nordisk A/S (NVO).

Who are Taro Pharmaceutical Industries' key executives?

Taro Pharmaceutical Industries' management team includes the following people:
  • Mr. Uday V. Baldota, CEO & Director (Age 49)
  • Mr. Mariano Balaguer, CFO, Chief Accounting Officer & VP (Age 46)
  • Mr. Itamar Karsenti, VP & Head of Global Operations (Age 47)
  • Mr. Itzik Baruch, VP of Technical Services (Age 56)
  • Dr. Roman Kaplan Ph.D., VP of Scientific and Technical Compliance Mang. (Age 72)

What is Taro Pharmaceutical Industries' stock symbol?

Taro Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TARO."

How do I buy shares of Taro Pharmaceutical Industries?

Shares of TARO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Taro Pharmaceutical Industries' stock price today?

One share of TARO stock can currently be purchased for approximately $65.63.

How big of a company is Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries has a market capitalization of $2.51 billion and generates $644.77 million in revenue each year. The company earns $244.24 million in net income (profit) each year or $6.35 on an earnings per share basis. Taro Pharmaceutical Industries employs 1,464 workers across the globe.

What is Taro Pharmaceutical Industries' official website?

The official website for Taro Pharmaceutical Industries is www.taro.com.

How can I contact Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries' mailing address is 14 HAKITOR ST PO BOX 10347, HAIFA BAY L3, 10532. The company can be reached via phone at 914-345-9000 or via email at [email protected]

This page was last updated on 7/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.